thirty-five previously untreated patients with multiple myeloma were treated with a 60-week course of alternating , potentially non-cross-resistant chemotherapy combinations ( melphalan and prednisone ; vincristine , cyclophosphamide , doxorubicin , and prednisone ; and carmustine , melphalan , and prednisone ) , alternating every 15 weeks in an attempt to prevent the development of drug resistance .
C0026764
multiple myeloma
C0025241
melphalan